Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status
Aurobindo Pharma's ANDA for Risendronate Sodium has been granted Abbreviated Approval (AP) status by the FDA.
Therapeutic Area
Therapeutic area intelligence for Bone Health with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.